Switch to Dolutegravir Regimen Improves Lipid Profile in HIV+ Patients
Investigators performed a randomized, noninferiority, 96-week, strategic trial of dolutegravir to compare efficacy and effect on lipid parameters.
Carotid artery plaque was predictive of mortality, with differences observed by sex and HIV serostatus.
Co-infection of HIV+ and tuberculosis (TB) may be associated with decreased neurological and neuropsychological functioning.
Lopinavir/ritonavir-based treatment may be associated with higher total cholesterol in young children.